In this episode of From the helm, Bell Financial Group’s Grady Wulff speaks with Proteomics International Laboratories (ASX: PIQ) CEO, Dr. Richard Lipscombe, about the company’s ground breaking work in predictive diagnostics and the global opportunity for its world-first blood tests.In this video, Dr. Lipscombe covers:·      (0:47): An overview of PIQ and its FY26 goals·      (1:38): The significance of three world-first blood tests·      (5:26): The global addressable markets for these conditions·      (6:25): Clinical trial progress and commercialisation roadmap·      (8:14): How the diagnostic tests work and deliver value to patients·      (9:16): Commercialisation strategy across key regions·      (11:23): Additional assets in the PIQ pipeline·      (12:36): What investors can expect over the next 12 monthsNote: This interview was recorded on 3 July 2025.

Ver todos los episodios